- HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy
- • At the 12 mg dose, cohorts demonstrated favorable activity and safety profile:
- – 63% ORR; with 53% VGPR or better –
- – CRS reported in 16% of patients, no Grade 3 events, no ICANS –
- • Findings support further clinical development at the 12 mg RP2D
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported data from the Phase 1 study of HPN217 in patients with RRMM in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. Harpoon also announced the selection of 12 mg as the HPN217 RP2D.
